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Background: Several studies investigated the combination of bare metal stents in the main branch and drug-
eluting balloons in the side branch in bifurcation lesions, but data on the combination of drug-eluting stents
and drug-eluting balloons are scarce. We aim to assess the feasibility of provisional stenting with an
everolimus-eluting stent in the main branch and a paclitaxel-eluting balloon in the side branch.
Methods: In this prospective, multi-center study conducted in 5 Australian sites, 35 patients with bifurcation le-
sions were enrolled. Angiographic and intravascular ultrasound assessments were conducted at 9 months; clin-
ical follow-up was conducted until 12 months.
Results: The primary endpoint, late lumen loss in the side branch measured by quantitative coronary angiogra-
phy, was 0.10 ± 0.43 mm. No binary restenosis was observed. One patient died; 3 myocardial infarctions (one
suspected and two in non-target vessels) and one target lesion revascularization occurred. No probable or deﬁ-
nite stent thrombosis was observed.
Conclusion: The combination of an everolimus-eluting stent in themainbranch and a paclitaxel-eluting balloon in
the side branch appears to be a safe, effective and novel treatment option for bifurcation lesions.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).THC, butyryltri-n-hexyl citrate.
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Bifurcation lesions account for approximately 15% of contemporary
percutaneous coronary interventions (PCIs) and are amongst the most
technically challenging lesion subsets in PCIs [1–3]. In the past years,
the introduction of drug-eluting stents (DESs) has signiﬁcantly im-
proved outcomes [3], andmeanwhile, provisional stenting is considered
to be the preferable approach for most of the bifurcation lesions [1–4].
Still, the dilemma of reducing side branch restenosis remains and fur-
ther investigation into devices that may help to reduce restenosis in bi-
furcation lesions is warranted.
Drug-eluting balloons (DEBs), being successfully deployed in several
indications in coronary and peripheral artery disease [5], could be a
promising treatmentmodality to reduce side branch restenosis. The up-
dated consensus group recommendations from Kleber et al. [1] as well
as a publication of Mathey et al. [6] suggested that provisional stenting
withDES in themainbranchandDEB in the side branchmight be a valu-
able treatment option which warrants scientiﬁc evaluation. Wethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with an everolimus-eluting stent in the main branch and a paclitaxel-
eluting balloon in the side branch. To the best of our knowledge, only
one single center study investigating the combination of DES in the
main branch and DEB in the side branch has been published to date
[7]. In contrast to BIOLUX-I, this single-center study used the same
drug –paclitaxel – for DEB and DES, whereas our study combines a
paclitaxel-eluting DEB with a state of the art everolimus-eluting DES.
2. Methods
2.1. Study design and population
BIOLUX-I is a prospective, multi-center, single arm pilot study to as-
sess the feasibility and safety of the Pantera Lux DEB (Biotronik AG,
Buelach, Switzerland) for the treatment of symptomatic single de novobi-
furcation lesions which are appropriate for provisional stenting tech-
nique. Patients were enrolled between January 2011 and August 2012.
The trial is registered at www.anzctr.org.au, ID 335843, where the full
set of general in- and exclusion criteria is available. Speciﬁc angiographic
inclusion criteria were: Either a single target lesion or two lesions (target
and non-target) located in separate coronary arteries. If a non-target le-
sion was treated, it had to be treated ﬁrst. Further, the target lesion had
to be a single de novo bifurcation lesion involving a coronary artery
with a reference vessel diameter of 2.0 to 4.0 mm in the main branch
and side branch with a main branch stenosis of ≥50% and b100%. Lastly,
a target vessel thrombolysis in myocardial infarction (TIMI) ﬂow ≥2
was required. Speciﬁc angiographic exclusion criteria were: Target lesion
location in a vessel which has a bypass graft, signiﬁcant stenosis (N50%)
proximal or distal to the target lesion thatmight require revascularization
or impede runoff, excessively tortuous target vessel (two bends N90° to
reach the target lesion), aorto-ostial or unprotected leftmain target lesion
or target lesion within 5 mm of the origin of the left anterior descending,
left circumﬂex, or right coronary artery, severely calciﬁed target lesion, or
evidence of a thrombus, further co-existence of unprotected leftmain dis-
ease (obstruction of N50%).Baseline N=35
- Death N=1
- Consent withd
- No office visit
- Not analyzable
- Refused angio
- No IVUS asse
9 Months
Clinical FUP N=33
Angiographic FUP N=28
IVUS FUP N=25
12 Months
Clinical FUP N=33
Fig. 1. Patient ﬂow diagram. FUP, followClinical assessments were scheduled at 1, 6, 9 and 12 months. At
9 months additionally angiography and intravascular ultrasound
(IVUS) were performed. It was recommended to either use clopidogrel
or prasugrel for 6 months and acetylsalicylic acid indeﬁnitely post-
procedure. Monitoring included 10% source document veriﬁcation of
key variables. Project and site management aswell as data coordination
and adjudication was organized by an independent Clinical Research
Organization. The Safety Monitoring Committee was composed of phy-
sicians from the ﬁelds of interventional cardiologywhowere not direct-
ly involved in the conduct of the trial. Angiographic and IVUS
assessments were done by an independent core laboratory. Ethics com-
mittee approval was obtained for all participating institutions and the
clinical trial was conducted in accordance with Good Clinical Practice
and ISO14155 as well as local regulations and applicable regulatory re-
quirements. All patients provided written informed consent.
2.2. Procedure
The surface of the Pantera Lux DEB is homogenously coated with a
delivery matrix of 3 μg paclitaxel per mm2 using butyryltri-n-hexyl cit-
rate (BTHC) as an excipient. BTHC incorporates paclitaxel into a micro-
crystalline structure to improve drug uptake into the vessel wall [8,9]. It
degrades to citric acid and alcohol. Paclitaxel is a lipophilic anti-
proliferative substance that allows a rapid drug absorption by the sur-
rounding tissue. The DEB was available in lengths of 10 to 30 mm
with diameters of 2.0 to 4.0 mm.
Pre-dilatation of the main branch with a standard balloon catheter
was required. Then, the side branch was treated with Pantera Lux and
the main branch with a DES (XienceV/Xience Prime, Abbott Vascular,
Santa Clara, CA, USA). Post-dilatation in the main branch was allowed
at the investigator’s discretion in order to achieve optimal stent deploy-
ment (residual diameter stenosis b10%). Thereafter, kissing balloon in-
ﬂation with standard balloons had to be performed. Stenting of the
side branch was deemed appropriate in the following cases: prolonged
ischemia (attributable to a side branch complication), TIMI Grade ﬂow0
or 1, dissection in the side branch, N70% residual stenosis.rawal N=1
N=1
by angiography N=1
graphy and IVUS N=3
ssment due to difficult anatomy N=4
-up; IVUS, intravascular ultrasound.
Table 1
Patient baseline and lesion data.
Patient baseline and lesion data
Demographics
Mean age ± SD (years) 65.9 ± 9.5
Min–Max 50–82
Male gender 82.8% (29/35)
Medical history
History of smoking 74.3% (26/35)
Diabetes mellitus 22.9% (8/35)
History of hypertension 68.6% (24/35)
History of hyperlipidemia 82.8% (29/35)
Premature CAD in a ﬁrst degree relativea 41.2% (14/34)
Previous CABG 2.9% (1/35)
Previous PCI 22.9% (8/35)
Stroke or TIA in Last 6 Months 2.9% (1/35)
Mean LVEF (%) 68 ± 10.4%
CCS Class
Class I 28.6% (10/35)
Class II 42.9% (15/35)
Class III 8.6% (3/35)
Class IV 2.9% (1/35)
No angina 48.6% (6/35)
Medina classiﬁcationb
1,1,1 23.3% (7/30)
1,1,0 46.6% (14/30)
1,0,1 3.3% (1/30)
1,0,0 16.7% (5/30)
0,1,1 10.0% (3/30)
0,1,0 16.7% (5/30)
Bifurcation treated
LAD 82.8% (29/35)
LCX 8.6% (3/35)
RCA 8.6% (3/35)
Previous stenting of MB or SB 0.0% (0/35)
Angulation between distal MB and SB b 70° 51.4% (18/35)
CABG, coronary artery bypass graft; CAD, coronary artery disease, Canadian Cardiovascular
Society classiﬁcation; LAD, left anterior descending; LCX, left circumﬂex; LVEF, left ventric-
ular ejection fraction; MB, main branch; PCI, percutaneous coronary intervention; RCA,
right coronary artery; SB, side branch; TIA, transient ischemic attack.
Values are mean ± SD when appropriate.
a Unknown for 1 patient.
b By visual estimate.
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Lesions were deﬁned according the Medina classiﬁcation [10]. The
primary endpoint was late lumen loss (LLL) of the side branch at
9 months by quantitative coronary angiography (QCA), deﬁned as the
difference between the post-index procedure minimal lumen diameter
(MLD) and the follow-up MLD. Secondary endpoints were device suc-
cess, deﬁned as ﬁnal residual diameter stenosis of b30% by QCA in the
side branch, using the assigned device only, procedural success, deﬁned
as ﬁnal diameter stenosis b30% by QCA in the side branch and main
branch, using the study device, without the occurrence of death, myo-
cardial infarction or repeat target lesion revascularization (TLR) during
the hospital stay, and lesion success, deﬁned as ﬁnal residual diameter
stenosis of b30% by QCA in the side branch without the need for other
lesion treatment (like cutting balloon, atherectomy) during the index
procedure. Furthermore, a composite of cardiac death, target-vessel
myocardial infarction and clinically driven target vessel revasculariza-
tion (TVR) was assessed at 6, 9 and 12 months, clinically driven TLR at
6, 9 and 12 months and binary angiographic restenosis at 9 months, as
measured by QCA. Deﬁnitions of cardiac death, myocardial infarction
and TLR and stent thrombosis were according to the ARC-Academic Re-
search Consortium guidelines [11].
2.4. Statistical analysis
The analysis was based on the principle of intention-to-treat (ITT).
For this study, all subjects who met the study entry criteria, signed the
written informed consent and were enrolled in the trial were counted
in the intention-to-treat analysis. The primary analysis consists of de-
scriptive statistics. These are presented as the mean and standard devi-
ation for continuous variables and as frequencies and percentages for
discrete variables.
3. Results
3.1. Baseline data
In BIOLUX-I, 35 patients were enrolled in 5 Australian centers. The
patient ﬂow is displayed in Fig. 1. Patients treated were predominantly
male (82.8%), nearly one quarter had diabetes (22.9%) or previous per-
cutaneous coronary interventions (PCIs) (22.9%). Lesions were mostly
located in the left anterior descending artery (82.9%) (Table 1).
3.2. Procedural data
Per site assessment 26 patients (74.3%) had true bifurcation lesions
with ≥50% stenosis in both branches, per visual core laboratory assess-
ment 11 patients (31.4%) had true bifurcations Medina X,X,1
(Table 1), and per QCA 3 patients (8.6%). Concomitant non-target lesion
treatmentwas performed in 5 patients (14.3%). In themain branch, 3 le-
sions were treated with 2 overlapping stents and one bailout stent was
used to treat a small dissection. In one patient, the Pantera Lux DEBwas
unable to pass through the side branch. After pre- dilatationwith an un-
coated balloon, the DEB could be successfully deployed. Four additional
stents were used in the side branch, all for treating vessel dissections
(Table 2). Post-procedure side branch stenosis ranged from 3.34% to
49.96%, and 9 patients had a side branch stenosis ≥30%, resulting in a de-
vice success rate of 60.0% (21/35). Procedure and lesion success rates
were 71.4% and 74.3% respectively.
3.3. Follow-up data
Angiographic and IVUS follow-up data are displayed in Table 3. LLL in
the side branchwas 0.10± 0.43mmper QCA and−0.03± 0.22mmper
IVUS assessment in the overall population (Table 3, Fig. 2) and 0.06 ±0.41 mm in patients with true bifurcation per core laboratory analysis.
No binary restenosis occurred.
At 12-month follow-up all patients werewithout symptoms of angi-
na except one with CCS class I.
Clinical outcomes are displayed in Table 4. The composite endpoint of
cardiac death, target-vessel myocardial infarction and clinically driven
TVR was 5.9%. One patient with Medina class 1,1,0, non-target lesion
treatment, post-dilatation and stenting of the side branch was found
dead at home 4.5 months post-procedure. The general practitioner
assessed the cause of death as suspectedmyocardial infarction secondary
to ischemic heart disease. No autopsy was performed. Per ARC deﬁni-
tion [11], the event was further classiﬁed as cardiac death and possible
stent thrombosis. Two further non-target vessel myocardial infarctions
occurred, one pre-procedure and one at 2.5 months. One clinically driven
TLRwas performedmore than 9months post-procedure in a patientwho
had Medina class 0,1,1 at baseline and a main branch bailout during pro-
cedure. This patient had a left main stenosis and aortic stenosis and re-
ceived a coronary artery bypass graft and aortic valve replacement.
4. Discussion
To the best of our knowledge, this is the ﬁrst multicentre study
assessing the feasibility of provisional stenting with a combination of
DES in the main branch and DEB in the side branch, using different
drugs. Adjudicated endpoints and independent angiographic and IVUS
core laboratories add to the strength of the study.
Table 2
Procedural data.
Procedural data
Main Branch
Pre-dilatation 97.1% (34/35)
Xience Prime 97.1% (34/35)
Xience V 2.9% (1/35)
Post-procedure dilatation rates
1 balloon 48.6% (17/35)
2 balloons 40.0% (14/35)
≥3 balloons 11.4% (4/35)
Main vessel bailout 2.9% (1/35)
Side branch
Dilatation (uncoated balloon)
1 balloon 17.1% (6/35)
≥2 balloons 20.0% (7/35)
Side branch bailout requiring stenting 11.4% (4/35)
416 S. Worthley et al. / Cardiovascular Revascularization Medicine 16 (2015) 413–417The potential role of DEB in bifurcation lesions is to maintain the
simplicity of provisional stenting with the advantage of reducing reste-
nosis of the side branch. However, the combination of pre-dilatation
with a DEB followed by main branch stenting with a bare metal stent
appears to be inferior to DES plus uncoated balloon due to insufﬁcient
results in the main branch and similar results in the side branch
[12,13]. Another treatment option is the combination of DES in the
main branch and DEB in the side branch, which could potentially over-
come the limitation of insufﬁcient results of the DEB plus bare metal
stent combination in themainbranch. In a single-center study, Herrador
et al. [7] compared patients treated with a paclitaxel-eluting balloon in
the side branch and a paclitaxel-eluting stent in themain branchwith a
historical control of patients with uncoated balloon treatment in the
side branch. Side branch stenosis and LLL at 9monthswere signiﬁcantly
lower in the DEB group compared with the uncoated balloon group
(25 ± 16% versus 36 ± 21%, p = 0.01 and 0.09 ± 0.4 mm versus
0.40 ± 0.5 mm, p = 0.01) and numerically less restenosis of the side
branch occurred in the DEB group (7% versus 20%, p = 0.08). Main
branch LLL was 0.49 ± 0.6 and 0.62 ± 0.7 respectively.
We assessed the combination of a paclitaxel-eluting DEB in the side
branchwith an everolimus-eluting stent in themain branch and found–
despite the very small baseline side branch diameter of only 2.06±0.39
– excellent angiographic follow-up data which are comparable to those
previously reported for DES/ uncoated balloon combinations and DES/
DEB combinations. Speciﬁcally, LLL of the side branch was 0.10 ±
0.43mmcompared to−0.13mm to 0.11mm for DES/uncoated balloon
and DES/DEB combinations (and LLL of the main branch was 0.28 ±Table 3
Angiographic and IVUS results.
Angiographic results Main branch
Pre-procedure Post-procedure 9-m
RVD (mm) 2.65 ± 0.57 3.03 ± 0.56 2.8
Lesion length (mm) 18.6 ± 6.0 – –
MLD (mm) 1.47 ± 0.45 2.76 ± 0.58 2.5
Diameter stenosis (%) 43.2 ± 16.8 9.1 ± 5.5 12.
Binary restenosis – – 0.0
Late lumen loss (mm) – – 0.2
IVUS results Main branch
MLD (mm) – 2.95 ± 0.35 2.9
MinLA (mm2) – 6.23 ± 1.54 6.1
LL diameter (mm) – – 0.0
LL lumen area (mm2) – – 0.3
Stent eccentricity indexa – 0.85 ± 0.04 0.8
ISAb – 25.8% (8/31) 11.
ISA, incomplete stent apposition; IVUS, intravascular ultrasound; LL, late loss; MinLA, minimal
Values are mean ± SD when appropriate.
a Minimal lumen diameter/maximal lumen diameter.
b Deﬁned as a separation of at least one stent strut from the intimal surface of the arter
side branches.0.59mm versus−0.06 mm to 0.49mm) [7,12–14]. Side branch diame-
ter stenosis was 22.6% ± 12.5% versus 25% to 33% and binary restenosis
was 0% compared to 7% to 20% for the side branch and 11% to 19% over-
all [7,12–14]. Notably, some patients had a negative LLL. With these
small patient numbers, the underlying reason cannot be clariﬁed. Even-
tually, it was caused by vessel-remodeling or by assessing different
areas of the vessel as the treated lesion often cannot be accurately locat-
ed when a stent is not implanted.
Overall, the angiographic parameters have to be interpreted taking
into account the moderate pre-procedure stenosis of 45.0% ± 15.2% in
the main branch and 30.1% ± 16.4% in the side branch, as assessed by
QCA. Only 11 patients (31.4%) had true bifurcation lesions by visual es-
timate by the core laboratory. However, when assessing patients with
true bifurcation lesions separately, LLL was 0.06 ± 0.41, suggesting
that the DEB is equally effective in true bifurcation lesions. Notably,
there was a prominent difference between the core laboratory and
site assessment and even between visual estimation and QCA assess-
ment of the core laboratory. Eventually, the very small vessel reference
diameter of 2.01 ± 0.43 hampered a consistent assessment. According
to site data, 26 patients (74.3%) had a ≥50% side branch and main
branch stenosis. This is especially interesting since a recent article com-
pared the site assessment versus angiographic core laboratory assess-
ment for 2013 records of the American College of Cardiology
Cardiovascular Data Registry and found only modest agreement be-
tween angiographic readings in clinical practice and those of an inde-
pendent core laboratory in regards to number of vessels affected
(kappa from 0.39 to 0.59 depending on the affected vessel; an agree-
ment in all vessels was only found in 60.9%). The authors concluded
that further studies are needed to assess the implications on patient
management [15]. Certainly, it is an indicator that for studies in bifurca-
tion lesions, core laboratories should always be consulted.
Except in one case, in which the DEB originally could not pass the le-
sion, and the lesion had to be pre-dilatedwith an uncoated balloon ﬁrst,
no side branch pre-dilatationwith an uncoated balloon was performed.
According to the results of the Nordic–Baltic Bifurcation Study III [14],
which showed that ﬁnal kissing balloon inﬂation with uncoated bal-
loons reduced angiographic side branch (re)stenosis, the protocol man-
dated ﬁnal kissing balloon inﬂation for procedural homogeneity.
However, a fair amount of discretion was allowed since there is no per-
fect way to treat bifurcations. In the end, only 37.2% (13/35) of the pa-
tients were treated with an uncoated balloon in the side branch in
addition to the DEB treatment, reﬂecting the tendency to rather use
the simpler approach without ﬁnal-kissing balloon dilatation, which
has been shown to reduce the use of contrast media and procedureSide branch
onth FUP Pre-procedure Post-procedure 9-month FUP
5 ± 0.41 2.01 ± 0.43 2.08 ± 0.59 2.01 ± 0.43
5.51 ± 2.30 – –
0 ± 0.45 1.45 ± 0.44 1.66 ± 0.47 1.52 ± 0.31
4 ± 9.2 26.8 ± 16.9 21.5 ± 13.1 22.6 ± 12.2
% (0/28) – – 0.0% (0/28)
8 ± 0.59 – – 0.10 ± 0.43
Side branch
9 ± 0.35 – 2.23 ± 0.31 2.28 ± 0.28
2 ± 1.54 – 3.47 ± 1.06 3.40 ± 0.78
1 ± 0.12 – – −0.03 ± 0.22
3 ± 0.65 – – 0.14 ± 0.78
6 ± 0.03 – – –
5% (3/26) – 0.0% (0/2) –
lumen area; MLD, minimal lumen diameter; RVD, reference vessel diameter.
ial wall with evidence of blood speckling behind the stent struts without overlapping
Fig. 2. Late lumen loss of the side branch at 9 months. LLL, late lumen loss. Patients with
side branch stenting were excluded.
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states that kissing balloon inﬂation is not routinely required [3].
The acute success rates appear low. However, comparing themwith
other studies, it has to be considered that different deﬁnitions for acute
success exist. BIOLUX-I applied the most rigorous deﬁnition using a
threshold of side branch stenosis of b30%, whereas other studies
[6,7,12] used a threshold of b50%. Notably, in BIOLUX-I, no patient had
a post-procedure main branch stenosis ≥30% and only one patient had
a post-procedure side branch stenosis of ≥50% (49.96%). It would be de-
sirable that future ARC guidelines would include common deﬁnitions to
report acute success rates to allow comparing acute success results
across studies.
The complication rates were low with only one death, possibly due
to myocardial infarction, two additional non-target vessel myocardial
infarctions, one TLR, and no deﬁnite or probable stent thrombosis.
While the patient numbers are low and absolute values have to be
interpreted with caution, it is reasonable to conclude that the approach
of combining a paclitaxel-eluting balloon with an everolimus-eluting
stent is safe. Furthermore, aside from the angiographic and IVUS param-
eters the performance of this treatment modality is reﬂected in the re-
duction and maintenance of a low angina class at 12 months (Only
one patient met the CCS class 1 criteria, all others were asymptomatic.).
4.1. Limitations
While per site assessment, 74.3% of the patients had side and main
branch stenosis of ≥50% at baseline, only 11 patients were assessed as
having a true bifurcation lesion by the core laboratory. Clinical follow-
up ratewas excellentwith only one patientwithdrawing consent. How-
ever, only 28 patients attended the angiographic follow-up. Most im-
portantly, the BIOLUX-I study was a pilot study and inevitably the trialTable 4
Clinical outcomes during 12 months.
Clinical outcomes 6-month FUP 9-month FUP 12-month FUP
Composite endpointa 2.9% (1/35) 2.9% (1/35) 5.7% (2/35)
Cardiac deathb 2.9% (1/35) 2.9% (1/35) 2.9% (1/35)
Target-vessel MIb 2.9% (1/35) 2.9% (1/35) 2.9% (1/35)
Non-target-vessel MI 5.7% (2/35) 5.7% (2/35) 5.7% (2/35)
TVR 0.0% (0/35) 0.0% (0/35) 2.9% (1/35)
TLR 0.0% (0/35) 0.0% (0/35) 2.9% (1/35)
Probable or deﬁnite stent
thrombosis
0.0% (0/35) 0.0% (0/35) 0.0% (0/35)
FUP, follow-up; MI, myocardial infarction; TLR, clinically driven target lesion revasculari-
zation; TVR, clinically driven target vessel revascularization.
a Composite of cardiac death, target-vessel MI, and clinically driven TVR.
b One patient was found dead. Possible cause of death was determined as myocardial
infarction.is limited by a small sample size of 35 patients. Consequently, large
scale randomized trials may be warranted to further investigate the
use of this treatment modality. Thereby the combination of DES/DEB
versus DES/uncoated balloon appears to be of special interest.
5. Conclusion
The combination treatment using the Xience V/ Xience Prime DES in
the main branch and the Pantera Lux DEB in the side branch appears to
be a safe, effective and novel treatment option for bifurcation lesions
with low late lumen loss in the main and side branches.
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